Small-molecule inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold

被引:129
|
作者
Hardcastle, Ian R.
Ahmed, Shafiq U.
Atkins, Helen
Farnie, Gillian
Golding, Bernard T.
Griffin, Roger J.
Guyenne, Sabrina
Hutton, Claire
Kallblad, Per
Kemp, Stuart J.
Kitching, Martin S.
Newell, David R.
Norbedo, Stefano
Northen, Julian S.
Reid, Rebecca J.
Saravanan, K.
Willems, Henriette M. G.
Lunec, John
机构
[1] Univ Newcastle Upon Tyne, No Inst Canc Res, Sch Nat Sci Chem, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England
[2] Univ Newcastle Upon Tyne, Sch Med, No Inst Canc Res, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England
[3] De Novo Pharmaceut, Cambridge CB4 9ZR, England
关键词
D O I
10.1021/jm0601194
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
From a set of weakly potent lead compounds, using in silico screening and small library synthesis, a series of 2-alkyl-3-aryl-3-alkoxyisoindolinones has been identified as inhibitors of the MDM2-p53 interaction. Two of the most potent compounds, 2-benzyl-3-(4-chlorophenyl)-3-(3-hydroxypropoxy)-2,3-dihydroisoindol-1-one (76; IC50 = 15.9 +/- 0.8 mu M) and 3-(4-chlorophenyl)-3-(4-hydroxy-3,5-dimethoxybenzyloxy)-2-propyl-2,3-dihydroisoindol-1-one (79; IC50) 5.3 (0.9 mu M), induced p53-dependent gene transcription, in a dose-dependent manner, in the MDM2 amplified, SJSA human sarcoma cell line.
引用
收藏
页码:6209 / 6221
页数:13
相关论文
共 50 条
  • [1] Inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold.
    Hardcastle, IR
    Ahmed, SU
    Barrett, PA
    Endicott, JA
    Golding, BT
    Griffin, RJ
    Gruber, J
    Hutton, C
    Kemp, SJ
    Lunec, J
    Noble, ME
    Riedinger, C
    Smyth, LA
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9053S - 9054S
  • [2] Isoindolinone based inhibitors of the MDM2-p53 protein-protein interaction
    Kemp, SJ
    Hardcastle, IR
    Ahmed, SU
    Atatreh, NA
    Barrett, P
    Endicott, JA
    Golding, BT
    Griffin, RJ
    Gruber, J
    Hutton, C
    Lunec, J
    Noble, MEM
    Reid, RJ
    Riedinger, C
    Smyth, LA
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 230 : U2735 - U2736
  • [3] Isoindolinone-based inhibitors of the MDM2-p53 protein-protein interaction
    Hardcastle, IR
    Ahmed, SU
    Atkins, H
    Calvert, AH
    Curtin, NJ
    Farnie, G
    Golding, BT
    Griffin, RJ
    Guyenne, S
    Hutton, C
    Källbad, P
    Kemp, SJ
    Kitching, MS
    Newell, DR
    Norbedo, S
    Northen, JS
    Reid, RJ
    Saravanan, K
    Willems, HMG
    Lunec, J
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (05) : 1515 - 1520
  • [4] MEDI 147-Isoindolinone-based inhibitors of the MDM2-p53 protein-protein interaction
    Watson, Anna F.
    Golding, Bernard T.
    Griffin, Roger J.
    Hutton, Claire
    Liu, Junfeng
    Lu, Xiaohong
    Lunec, John
    Newell, David R.
    Valeur, Eric
    Hardcastle, Ian R.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2008, 236
  • [5] Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction (MDM2 Inhibitors) in Clinical Trials for Cancer Treatment
    Zhao, Yujun
    Aguilar, Angelo
    Bernard, Denzil
    Wang, Shaomeng
    JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (03) : 1038 - 1052
  • [6] Development of a potent class of small molecule inhibitors of the MDM2-p53 protein-protein interaction
    Fazal, Lynsey
    Ahn, Maria
    Bevan, Luke
    Buck, Ildiko
    Castro, Juan
    Chessari, Gianni
    Cons, Ben
    Hearn, Keisha
    Howard, Steven
    Johnson, Chris
    Reeks, Judith
    Tamanini, Emiliano
    Thompson, Neil
    Walton, Hugh
    Williams, Pamela
    Bawn, Ruth H.
    Blackburn, Tim J.
    Cano, Celine
    Cully, Sarah J.
    Golding, Bernard
    Griffin, Roger
    Haggerty, Karen
    Hardcastle, Ian
    Newell, Herbie
    Noble, Martin
    Thomas, Huw
    Willmore, Elaine
    Zhao, Yan
    Wedge, Steve
    CANCER RESEARCH, 2018, 78 (13)
  • [7] Recent Small-Molecule Inhibitors of the p53-MDM2 Protein-Protein Interaction
    Beloglazkina, Anastasia
    Zyk, Nikolai
    Majouga, Alexander
    Beloglazkina, Elena
    MOLECULES, 2020, 25 (05):
  • [8] Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction to Reactivate p53 Function: A Novel Approach for Cancer Therapy
    Shangary, Sanjeev
    Wang, Shaomeng
    ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2009, 49 : 223 - 241
  • [9] Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Protein-Protein Interaction
    Chessari, Gianni
    Hardcastle, Ian R.
    Ahn, Jong Sook
    Anil, Burcu
    Anscombe, Elizabeth
    Bawn, Ruth H.
    Bevan, Luke D.
    Blackburn, Timothy J.
    Buck, Ildiko
    Cano, Celine
    Carbain, Benoit
    Castro, Juan
    Cons, Ben
    Cully, Sarah J.
    Endicott, Jane A.
    Fazal, Lynsey
    Golding, Bernard T.
    Griffin, Roger J.
    Haggerty, Karen
    Harnor, Suzannah J.
    Hearn, Keisha
    Hobson, Stephen
    Holvey, Rhian S.
    Howard, Steven
    Jennings, Claire E.
    Johnson, Christopher N.
    Lunec, John
    Miller, Duncan C.
    Newell, David R.
    Noble, Martin E. M.
    Reeks, Judith
    Revill, Charlotte H.
    Riedinger, Christiane
    St Denis, Jeffrey D.
    Tamanini, Emiliano
    Thomas, Huw
    Thompson, Neil T.
    Vinkovic, Mladen
    Wedge, Stephen R.
    Williams, Pamela A.
    Wilsher, Nicola E.
    Zhang, Bian
    Zhao, Yan
    JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (07) : 4071 - 4088
  • [10] Discovery of MDM2-p53 and MDM4-p53 protein-protein interactions small molecule dual inhibitors
    Espadinha, Margarida
    Lopes, Elizabeth A.
    Marques, Vanda
    Amaral, Joana D.
    dos Santos, Daniel J. V. A.
    Mori, Mattia
    Daniele, Simona
    Piccarducci, Rebecca
    Zappelli, Elisa
    Martini, Claudia
    Rodrigues, Cecilia M. P.
    Santos, Maria M. M.
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 241